6th independent analysis showing efficacy from the Boulware PEP trial. This prospective analysis corrects an error in the NEJM paper where shipping delays are omitted (still not corrected).
42% reduction in COVID-19 (9.6% vs. 16.5%), RR 0.58 [0.35 - 0.97], p
=0.044, for the original trial 3 day specification.
Wiseman et al., 12/2/2020, preprint, 4 authors.
risk of COVID-19 case, 42.0% lower, RR 0.58, p = 0.04, <= 3 days after exposure.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.